Advances in Urology

Urothelial Carcinoma


Publishing date
03 Aug 2012
Status
Published
Submission deadline
16 Mar 2012

Lead Editor

1Department of Pathology, College of Medicine, National Cheng Kung University, No. 1 University Road, Tainan 701, Taiwan

2Section of Experimental Oncology, Cancer Research UK Clinical Centre, Leeds Institute for Molecular Medicine, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK

3The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, 600 N. Wolfe Street, Marburg 409, Baltimore, MD 21287, USA


Urothelial Carcinoma

Description

Bladder cancer is a common urologic cancer. In North America, South America, Europe, and Asia, the most common type of epithelial tumor diagnosed is urothelial (transitional cell) carcinoma. Worldwide, however, squamous cell carcinoma (SCC) is the most common form of bladder cancer, accounting for 75% of cases in developing nations. Urothelial carcinoma of the bladder is intriguing to both biologists and oncologists. Clinical management of this type of bladder cancer is challenging for its heterogeneity among bladder tumors with respect to invasion and metastasis, and frequent recurrence in the bladder among patients treated with bladder preservation therapies. The dilemma of clinical practice has stimulated the translational research. At the same time, the characteristics of environment-driven carcinogenesis and divergent molecular pathways in the development of low- and high-grade tumors provide a unique opportunity for molecular research in cancer biology. Bladder cancer is also at the forefront of biomarker development because of the ease of developing noninvasive urine tests. The objective of this special issue is to present both reviews of translational research in the bladder cancer and up-to-date summaries related to molecular pathogenesis, diagnosis, prognostic assessment, and management of bladder cancer. It is hoped that this volume can bring the latest information to all urologists, pathologists, and medical oncologists who wish to provide their patients with the most comprehensive care.

We invite investigators to contribute original work, as well as review articles, for all aspects of bladder cancer research. We are particularly interested in articles describing the latest discoveries of tumor biology, cancer genetics, molecular epidemiology, novel therapeutics, and cancer prevention. The final goal of this issue is to stimulate the development of early detection, prevention, and treatment for human bladder cancer. Potential topics include, but are not limited to:

  • Recent developments of basic science research in urothelial bladder cancer
  • Advances in genetics of bladder cancer
  • Latest technologies for molecular diagnosis of bladder cancer
  • Role of molecular biomarkers in clinical evaluation and measuring outcomes
  • Recent progress in clinical management of patients with muscle-invasive bladder cancer, including urinary diversion and laparoscopic cystectomy
  • Recent progress in the prevention of urothelial carcinogenesis
  • Recent advances in epidemiology of urothelial bladder cancer
  • Advances in the development of targeted therapy for bladder cancer

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/au/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 461370
  • - Editorial

Urothelial Carcinoma

Nan-Haw Chow | Margaret Knowles | Trinity J. Bivalacqua
  • Special Issue
  • - Volume 2012
  • - Article ID 181964
  • - Review Article

Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

Yuh-Shyan Tsai | Hong-Lin Cheng | ... | Nan-Haw Chow
  • Special Issue
  • - Volume 2012
  • - Article ID 653652
  • - Review Article

The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer

Matthew E. Hyndman | Deborah Kaye | ... | Trinity J. Bivalacqua
  • Special Issue
  • - Volume 2012
  • - Article ID 142135
  • - Review Article

Muscle Invasive Bladder Cancer: From Diagnosis to Survivorship

N. E. Mohamed | M. A. Diefenbach | ... | S. J. Hall
  • Special Issue
  • - Volume 2012
  • - Article ID 429213
  • - Review Article

A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges

Erica di Martino | Darren C. Tomlinson | Margaret A. Knowles
  • Special Issue
  • - Volume 2012
  • - Article ID 404581
  • - Review Article

Oncolytic Viruses in the Treatment of Bladder Cancer

Kyle G. Potts | Mary M. Hitt | Ronald B. Moore
  • Special Issue
  • - Volume 2012
  • - Article ID 546917
  • - Review Article

Epigenetic Alterations in Bladder Cancer and Their Potential Clinical Implications

Han Han | Erika M. Wolff | Gangning Liang
  • Special Issue
  • - Volume 2012
  • - Article ID 181987
  • - Review Article

Bladder Cancer Immunotherapy: BCG and Beyond

Eric J. Askeland | Mark R. Newton | ... | Yi Luo
  • Special Issue
  • - Volume 2012
  • - Article ID 503271
  • - Review Article

Methylation Markers for Urine-Based Detection of Bladder Cancer: The Next Generation of Urinary Markers for Diagnosis and Surveillance of Bladder Cancer

Thomas Reinert
Advances in Urology
 Journal metrics
Acceptance rate19%
Submission to final decision60 days
Acceptance to publication39 days
CiteScore1.290
Impact Factor-
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.